A risk-adapted approach to acute GVHD treatment: Are we there yet?

Bone Marrow Transplantation

Volumn 51, Issue 2, 2016, Pages 172-175

  Holtan, S G ^a,b   Macmillan, M L ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; NATALIZUMAB; REGENERATING ISLET DERIVED 3 ALPHA; STEROID; SUPPRESSION OF TUMORIGENICITY 2; THROMBOMODULIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; AGE DISTRIBUTION; CELL DAMAGE; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL RATE; ACUTE DISEASE; ALLOGRAFT; BIOLOGICAL MODEL; GRAFT VS HOST DISEASE; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR;

ACUTE DISEASE; ALLOGRAFTS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84956906206     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.261     Document Type: Review

References (33)

1. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030
2. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-1472
3. Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-tobedside update. Blood 2014; 124: 363-373
4. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443-458
5. Koyama M, Kuns RD, Olver SD, Raffelt NC, Wilson YA, Don AL et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med 2011; 18: 135-142
6. Tichelli A, Gratwohl A. Vascular endothelium as 'novel' target of graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 139-148
7. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK et al. Response of 443 patients to steroids as primary therapy for acute graft-versushost disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387-394
8. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH et al. Steroidrefractory acute GVHD: predictors and outcomes. Adv Hematol 2011; 2011: 601953
9. Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 674-682
10. Almici C, Skert C, Verardi R, Di Palma A, Bianchetti A, Neva A et al. Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation 2014; 98: 706-712
11. Snover DC, Weisdorf SA, Ramsay NK, McGlave P, Kersey JH. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 1984; 4: 123-130
12. Dumler JS, Beschorner WE, Farmer ER, Di Gennaro KA, Saral R, Santos GW. Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol 1989; 135: 1097-1103
13. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 2010; 115: 5412-5417
14. Inamoto Y, Martin PJ, Storer BE, Mielcarek M, Storb RF, Carpenter PA. Response endpoints and failure-free survival after initial treatment for acute graft-versushost disease. Haematologica 2014; 99: 385-391
15. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant 2015; 21: 761-767
16. Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood 2014; 124: 287-295
17. Kim DH, Lee NY, Lee MH, Sohn SK. Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 1408-1416
18. Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F et al. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant 2015; 21: 1029-1036
19. Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011; 118: 1685-1692
20. Andrulis M, Dietrich S, Longerich T, Koschny R, Burian M, Schmitt-Graf A et al. Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease. Haematologica 2012; 97: 1674-1677
21. Rachakonda SP, Penack O, Dietrich S, Blau O, Blau IW, Radujkovic A et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol 2014; 32: 3421-3427
22. Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21: 1373-1383
23. Atkinson K, Farrell C, Chapman G, Downs K, Penny R, Biggs J. Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol 1986; 63: 231-239
24. MacMillan ML, For TE, Weisdorf DJ. What predicts high risk acute graft-versushost disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 2012; 157: 732-741
25. Paczesny S, Levine JE, Braun TM, Ferrara JL. Plasma biomarkers in graft-versushost disease: a new era? Biol Blood Marrow Transplant 2009; 15: 33-38
26. Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 2006; 34: 796-801
27. Wang H, Clouthier SG, Galchev V, Misek DE, Duffner U, Min CK et al. Intactprotein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 2005; 4: 618-625
28. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2015; 2: e21-e29
29. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005; 90: 939-948
30. Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C et al. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versushost disease after allogeneic stem cell transplantation. Ann Hematol 2014; 93: 855-861
31. Thoma MD, Glejf J, Jacob E, Huneke TJ, DeCook LJ, Johnson ND et al. Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant. BMC Hematol 2014; 14: 14
32. Pencina MJ, D'Agostino RB , D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172; discussion 207-12
33. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-864